Abstract: The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.

Abstract: The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Ring A, and R1 through R4 are as defined herein, and methods of making and using the same.

Abstract: The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.

Abstract: A wheel-tracking test device includes a housing, one or more test chambers in the housing, one or more load arm assemblies, and a drive mechanism. Each test chamber is configured to receive and hold one or more asphalt test samples. Each load arm assembly includes a weighted loading arm and a wheel rotatably connected to the loading arm. The drive mechanism is configured to move the load arm assembly from a load position in which the wheel is on a test sample held in the test chamber and a rest position by retracting the loading arm such that the wheel is lifted off the test sample.

Abstract: A wheel-tracking test device includes a housing, one or more test chambers in the housing, one or more load arm assemblies, and a drive mechanism. Each test chamber is configured to receive and hold one or more asphalt test samples. Each load arm assembly includes a weighted loading arm and a wheel rotatably connected to the loading arm. The drive mechanism is configured to move the load arm assembly from a load position in which the wheel is on a test sample held in the test chamber and a rest position by retracting the loading arm such that the wheel is lifted off the test sample.

Abstract: The present invention relates to agonists of the S1P4 receptor, which are selective for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, in particular new indol-alanine derivatives of structure I, process for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them wherein R1 is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C1-6alkyl, C1-6alkoxy or phenylC1-6alkyl; and R2 is hydrogen or C1-6alkyl; in free or salt form.

Abstract: The invention discloses the first known function and biological activity of the hypothetical protein MGC14327, now designated cMAC, which is herein identified as an important controller of T-cell activation. It is contemplated herein that cMAC is a suitable drug target for the development of new therapeutics to treat cMAC-associated disorders. The invention relates to methods to treat said pathological conditions and to pharmaceutical compositions therefore. The pharmaceutical compositions comprise modulators with inhibitory or agonist effect on cMAC protein activity and/or cMAC gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit or agonize cMAC protein activity and/or cMAC gene expression.

Abstract: The present invention relates to agonists of the S1P4 receptor, which are selective for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, in particular new indol-alanine derivatives of structure 1, process for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them wherein R1 is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C1-6alkyl, C1-6alkoxy or phenylC1-6alkyl; and R2 is hydrogen or C1-6alkyl; in free or salt form.